Cyclopharm (ASX:CYC) ROCE %: -50.21% (As of Dec. 2025)

What is Cyclopharm ROCE %?

Cyclopharm ASX:CYC 46 ROCE % is -50.21% as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cyclopharm's annualized ROCE % for the quarter that ended in Dec. 2025 was -50.21%.

Cyclopharm (ASX:CYC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cyclopharm ROCE % Related Terms

Cyclopharm ROCE % Historical Data

* Premium members only.

The historical data trend for Cyclopharm's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclopharm ROCE % Chart

Cyclopharm Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-12.21

-13.26

-10.57

-29.37

-41.24

Cyclopharm Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROCE %	Get a 7-Day Free Trial															-8.38	-32.92	-21.28	-32.66	-50.21

46GF Score

Cyclopharm Ltd ASX:CYC

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cyclopharm ROCE % Calculation

Cyclopharm's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-17.808	/	( ( (62.127 - 10.611)	+	(46.101 - 11.262) )	/ 2 )
	=	-17.808	/	( (51.516	+	34.839)	/ 2 )
	=	-17.808	/	43.1775
	=	-41.24 %

Cyclopharm's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Jun. 2025 )		(Q: Dec. 2025 )
	=	-19.93	/	( ( (55.913 - 11.363)	+	(46.101 - 11.262) )	/ 2 )
	=	-19.93	/	( ( 44.55	+	34.839 )	/ 2 )
	=	-19.93	/	39.6945
	=	-50.21 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -50.21% mean?

Cyclopharm (ASX:CYC) has a ROCE % of -50.21% as of Dec. 2025.

Is Cyclopharm's ROCE % too high?

Cyclopharm's current ROCE % is -50.21%. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Cyclopharm's ROCE % compare to MCK and COR?

Cyclopharm's ROCE % of -50.21% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Distribution company?

The median ROCE % among Medical Distribution companies is 9.09, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current ROCE % is -50.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cyclopharm stock overvalued right now?

Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current ROCE % is -50.21%. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current ROCE % is -50.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

ROCE %: -50.21%
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Industry Healthcare Medical Distribution

Comparable Companies ASX:MYX ASX:PGC MCK COR CAH ASX:SIG HSIC SHSE:601607 HKSE:01099 XSWX:GALE SHSE:600332 SHSE:600998 TSE:7459 OSTO:ASKER MIL:AMP SHSE:600511 TSE:2784 SHSE:600739 NZSE:EBO TSE:9987

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208

Website https://cyclopharm.com.au

Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.

46GF Score

Get the complete analysis for ASX:CYC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.50

Price

A$0.84

GF Value

View ASX:CYC Analysis

See ROCE % data for all stocks →